Opinion of the Scientific Committee on Veterinary

Total Page:16

File Type:pdf, Size:1020Kb

Opinion of the Scientific Committee on Veterinary EUROPEAN COMMISSION XXIV/B3/SC4 DIRECTORATE-GENERAL XXIV CONSUMER POLICY AND CONSUMER HEALTH PROTECTION Directorate B - Scientific Health Opinions Unit B3 - Management of scientific committees II OPINION OF THE SCIENTIFIC COMMITTEE ON VETERINARY MEASURES RELATING TO PUBLIC HEALTH ASSESSMENT OF POTENTIAL RISKS TO HUMAN HEALTH FROM HORMONE RESIDUES IN BOVINE MEAT AND MEAT PRODUCTS _________________________ 30 APRIL 1999 (references completed) INDEX 1. INTRODUCTION...................................................................................................1 1.1. Mandate.........................................................................................................1 1.2. Background....................................................................................................1 1.3. General considerations and introduction to the report: ....................................2 2. EMERGING CONCERNS RELATED TO HORMONALLY ACTIVE SUBSTANCES .......................................................................................................4 2.1. Definitions......................................................................................................4 2.2. Effects of hormones at different stages of life..................................................5 2.2.1. Effects of sex hormones during the intrauterine and perinatal periods on development ....................................................................5 2.2.2. Endocrine effects of sex hormones on growth and puberty in humans ........................................................................................... 11 2.2.3. Effects of sex hormones on reproduction......................................... 15 2.3. Human exposure to oestrogens and its relationship to cancer........................ 16 2.3.1. Descriptive epidemiology................................................................ 16 2.3.2. Etiologic epidemiology ................................................................... 17 2.3.3. Other hormonal effects relevant to cancer ....................................... 21 2.4. Sexual hormones and the immune system...................................................... 22 2.4.1. Sexual hormones and autoimmunity ................................................ 22 2.4.2. Sexual hormones and tolerance to the foetus in pregnancy; orientation of the immune response and allergic diseases ................. 23 2.5. OESTROGEN METABOLITES AS DNA-REACTIVE AND GENOTOXIC SUBSTANCES .................................................................... 24 2.5.1. DNA damage by oestrogen-3,4-quinones ........................................ 24 2.5.2. Properties of 4-Catechol-Oestrogens: Formation of Depurinating Adducts and Tumor Initiation..................................... 25 2.5.3. Redox Cycling of Catechol-Oestrogens, Their Semiquinones and Quinones.................................................................................. 26 2.5.4. Testing the genotoxicity of oestrogens ............................................ 27 I 3. GENERAL CONSIDERATIONS RELATING TO EXPOSURE ASSESSMENT ..................................................................................................... 27 3.1. Quantification of hormones in edible tissues.................................................. 27 3.2. Exposure in relation to endogenous hormone production in humans at different stages of life ................................................................................... 28 3.3. Exposure considerations upon misuse........................................................... 30 3.3.1. Misplaced implants.......................................................................... 30 3.3.2. Off-label use ................................................................................... 31 3.3.3. Black-market drugs......................................................................... 31 3.3.4. Secondary risks............................................................................... 32 4. CHARACTERISTICS OF THE INDIVIDUAL COMPOUNDS UNDER CONSIDERATION............................................................................................... 33 4.1. 17 β-oestradiol............................................................................................. 33 4.1.1. Pharmacokinetics and biotransformation of 17β-oestradiol in animals............................................................................................ 33 4.1.2. Oestradiol disposition in the target animal ....................................... 34 4.1.3. Interactions..................................................................................... 35 4.1.4. Pharmacokinetics and biotransformation of 17β-oestradiol in humans. .......................................................................................... 36 4.1.5. Assessment of excess exposure to oestrogens from consumption of hormone-treated beef ............................................. 36 4.1.6. Genotoxicity................................................................................... 39 4.1.7. DNA adducts and DNA damage ..................................................... 41 4.1.8. Carcinogenicity............................................................................... 42 4.1.9. Effects on growth and reproduction ................................................ 43 4.1.10. Effects on the immune system ......................................................... 44 4.2. Testosterone................................................................................................. 45 4.2.1. Pharmacokinetics and Biotransformation of Testosterone in animals............................................................................................ 46 4.2.2. Testosterone disposition in the target animal ................................... 46 II 4.2.3. Pharmacokinetics and Biotransformation (in humans)...................... 47 4.2.4. Assessment of Excess Exposure to testosterone from Consumption of Hormone-treated Beef........................................... 47 4.2.5. Mutagenicity and genotoxicity of testosterone................................. 49 4.2.6. DNA adducts and DNA damage ..................................................... 49 4.2.7. Carcinogenicity............................................................................... 49 4.2.8. Effects of testosterone on growth and reproduction ........................ 50 4.2.9. Effects of testosterone on the immune system ................................. 50 4.3. Progesterone ................................................................................................ 51 4.3.1. Pharmacokinetics and biotransformation of progesterone in animals............................................................................................ 51 4.3.2. Progesterone disposition in the target animal................................... 52 4.3.3. Pharmacokinetics and biotransformation of progesterone in humans ........................................................................................... 52 4.3.4. Assessment of excess exposure to progesterone from consumption of hormone-treated beef ............................................. 52 4.3.5. Mutagenicity and genotoxicity of progesterone ............................... 54 4.3.6. DNA adducts and DNA damage ..................................................... 54 4.3.7. Carcinogenicity............................................................................... 54 4.3.8. Effect of progesterone on growth and reproduction......................... 54 4.3.9. Effects of progesterone on the immune system................................ 55 4.4. Trenbolone................................................................................................... 55 4.4.1. Pharmacokinetics and biotransformation of trenbolone in animals............................................................................................ 55 4.4.2. Trenbolone disposition in the target animal...................................... 56 4.4.3. Pharmacokinetics and biotransformation of trenbolone in humans ........................................................................................... 56 4.4.4. Assessment of exposure to trenbolone from consumption of hormone-treated beef...................................................................... 57 4.4.5. Mutagenicity and genotoxicity ........................................................ 57 III 4.4.6. DNA adducts and DNA damage ..................................................... 59 4.4.7. Carcinogenicity............................................................................... 59 4.4.8. Effect of trenbolone on growth and reproduction ............................ 59 4.4.9. Effects of trenbolone on the immune system.................................... 60 4.5. Zeranol......................................................................................................... 60 4.5.1. Pharmacokinetics and biotransformation of zeranol in animals......... 60 4.5.2. Zeranol disposition in the target animal ........................................... 61 4.5.3. Pharmacokinetics and biotransformation of zeranol in humans......... 63 4.5.4. Assessment of exposure to zeranol from consumption of hormone-treated beef...................................................................... 63 4.5.5. Mutagenicity and genotoxicity of zeranol........................................ 64 4.5.6. DNA adducts and DNA damage ..................................................... 64 4.5.7. Carcinogenicity..............................................................................
Recommended publications
  • Method for the Detection of Zeranol and SOP : ARO/442 Taleranol In
    TITLE: Method for the detection of zeranol and S.O.P. : ARO/442 taleranol in meat and liver Page : 1 of 9 . Revision : 0 Date : 990715 1. INTRODUCTION 1.1 Summary This SOP describes a screening and confirmation method for the determination of resorcyclic acid lactones (RAL’s) in meat and liver samples of bovine origin. A procedure is described for the detection of a-zearalanol (zeranol) and b-zearalanol (taleranol) by a combination of solid phase extraction (SPE) and GC-MS. The method consist of, digestion of the meat sample using the enzyme protease and hydrolysis of the liver sample using suc d’Helix Pomatia, extraction of the RAL’s with tert-butylmethylether (TBME), purification using reversed-phase C18 cartridges. This method can also be used for the metabolites a-zearalenol, b-zearalenol, zearalanone and zearalenone. When doing so validation for these compounds is necessary. 1.2 Field of application The method is used to perform routine screening in meat and liver samples and has proven to be suitable for the analysis of a-zearalanol and b-zearalanol. The limit of detection is 0.5 mg/g based on the detection of the most abundant diagnostic ions namely m/z 433 and m/z 437 for the internal standard, with a response at the correct retention time exceeding the signal to noise ratio of 3. The method is validated according to SOP ARO/425 (1.3.3). 1.3 References 1.3.1. H.J. van Rossum et al, Multi residue analysis anabolic agents, SOP ARO/113, revision 4, 21 January 1997, RIVM.
    [Show full text]
  • Bipolar Androgen Therapy (BAT) in Men with Prostate Cancer
    Bipolar Androgen Therapy (BAT) in men with prostate cancer Samuel Denmeade, MD Professor of Oncology, Urology and Pharmacology The Johns Hopkins University School of Medicine, Baltimore, MD Presentation Overview • Androgen and Androgen Signaling 101 • Rationale For Bipolar Androgen Therapy (BAT) • Results from the RESTORE study testing BAT in Castration Resistant Prostate Cancer • The multi-center TRANSFORMER Trial • Future Directions • Results of BATMAN trial testing BAT as part of Intermittent Hormone Therapy strategy Testosterone Replacement Anabolic Steroids Trenbolone Acetate (Fina-Finaplix H pellets) High Dose Testosterone as Treatment for Prostate Cancer What Are Androgens? • Steroid hormone which can bind to Androgen Receptor – Testosterone, Dihydrotestosterone (DHT), DHEA, Androstenedione… • Sexual Differentiation – Needed to make a Male (Female is Default) • Primary Sex Characteristics: – Spermatogenesis – Accessory Sex Tissue Maintenance • Penis, Prostate... • Secondary Sex Characteristics: – Bone density – Muscle mass – Libido – Hair growth – Hematopoiesis What is a Steroid Hormone? Testosterone (T) Dihydrotestosterone (DHT) Estrogen How are Androgens Made? Androgen Receptor Signaling 101 Androgen Active Androgen Receptor (Testosterone) Androgen Receptor How Do Androgens Effect the Prostate Cell? NTD- Signaling Part DBD- DNA Binding Part LBD- Androgen Binding Part Cytoplasm Cell Nucleus Binds and activates genes: -Cell Growth -Cell Survival -Make prostate stuff like PSA, Acid Phosphatase, etc. DNA The Devilish Prostate • Physiologic
    [Show full text]
  • Record of Reasons for 16-18 November 1999 Meeting
    1 NATIONAL DRUGS AND POISONS SCHEDULE COMMITTEE MEETING 25 – 16-18 November 1999 RECORD OF REASONS FOR AMENDMENT TO THE STANDARD FOR THE UNIFORM SCHEDULING OF DRUGS AND POISONS AGRICULTURAL, VETERINARY AND DOMESTIC CHEMICALS Buprofezin – Schedule required Amendment and Reasons The decision below was based on buprofezin’s toxicological profile, in particular its acute oral toxicity. A cut-off to exempt at a concentration of 40% was agreed because of the reduced oral toxicity at this concentration and the ability of safety directions and warning statements applied through the registration system for agricultural and veterinary chemicals to adequately address the slight eye irritation which was attributed to the product formulation. Schedule 5 – New entry BUPROFEZIN except in preparations containing 40 per cent or less of buprofezin. Copper hydroxide - progression of foreshadowed decision to include copper hydroxide in Schedule 6 with cut-off to Schedule 5 at 50 per cent and to exempt at 12.5 per cent. Amendment and Reasons The amendment below was based on the acute oral toxicity of copper hydroxide, its severe eye irritancy / corrosivity, and the possibility of products containing copper hydroxide being accessible in domestic situations and therefore presenting a risk of accidental ingestion. Schedule 6 – New entry COPPER HYDROXIDE except: (a) when included in Schedule 5; or (b) in preparations containing 12.5 per cent or less of copper hydroxide. Schedule 5 – New entry COPPER HYDROXIDE in preparations containing 50 per cent or less of copper hydroxide except in preparations containing 12.5 per cent or less of copper hydroxide. Cyhexatin - Review of Appendix F warning statements and Appendix J rider.
    [Show full text]
  • Albany-Molecular-Research-Regulatory
    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
    [Show full text]
  • Étude in Vivo / in Vitro De L'effet De La Zéaralénone Sur L'expression De
    Étude in vivo / in vitro de l’effet de la zéaralénone sur l’expression de transporteurs ABC majeurs lors d’une exposition gestationnelle ou néonatale Farah Koraichi To cite this version: Farah Koraichi. Étude in vivo / in vitro de l’effet de la zéaralénone sur l’expression de transporteurs ABC majeurs lors d’une exposition gestationnelle ou néonatale. Toxicologie. Université Claude Bernard - Lyon I, 2012. Français. NNT : 2012LYO10314. tel-01071280 HAL Id: tel-01071280 https://tel.archives-ouvertes.fr/tel-01071280 Submitted on 3 Oct 2014 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. N° d’ordre 314-2012 Année 2012 THESE DE L’UNIVERSITE DE LYON Délivrée par L’UNIVERSITE CLAUDE BERNARD LYON 1 ECOLE DOCTORALE INTERDISCIPLINAIRE SCIENCES-SANTE (EDISS) DIPLOME DE DOCTORAT (arrêté du 7 août 2006) soutenue publiquement le 20 décembre 2012 par Mlle Farah KORAÏCHI TITRE : ETUDE IN VIVO/IN VITRO DE L’EFFET DE LA ZEARALENONE SUR l’EXPRESSION DE TRANSPORTEURS ABC MAJEURS LORS D’UNE EXPOSITION GESTATIONNELLE OU NEONATALE Directeur de thèse: Sylvaine LECOEUR Co-directeur
    [Show full text]
  • Expression of Recombinant Human Androgen Receptor and Its Use for Screening Methods
    Institut für Physiologie FML Weihenstephan Technische Universität München Expression of recombinant human androgen receptor and its use for screening methods Ellinor Rose Sigrid Bauer Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ.-Prof. Dr. B. Hock Prüfer der Dissertation: Univ.-Prof. Dr. H. H. D. Meyer Univ.-Prof. Dr. H. Sauerwein (Rheinische Friedrich-Wilhelms-Universität Bonn) Die Dissertation wurde am 31.10.2002 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 03.12.2002 angenommen. Introduction Content 1. INTRODUCTION ..................................................................................................................................... 5 1.1. ENDOCRINE DISRUPTERS 5 1.2. ANDROGENS AND ANTIANDROGENS 7 1.2.1. DEFINITIONS 7 1.2.2. MODE OF ACTION 8 1.3. STRUCTURES OF ENDOCRINE DISRUPTERS 10 1.4. STRATEGIES FOR MONITORING ANDROGEN ACTIVE SUBSTANCES 13 1.4.1. IN VIVO METHODS 13 1.4.2. IN VITRO METHODS 15 1.5. OBJEKTIVE OF THE STUDIES 18 2. MATERIALS AND METHODS ................................................................................................................. 19 2.1. PREPARATION OF RECEPTORS 19 2.2. ASSAY SYSTEMS 19 2.2.1. IN SOLUTION AR ASSAY 19 2.2.2. IMMUNO-IMMOBILISED RECEPTOR ASSAY (IRA) 20 2.2.3. PR AND SHBG ASSAYS 21 2.2.4. DATA EVALUATION 21 2.3. ANALYTES 22 3. RESULTS AND DISCUSSION ................................................................................................................. 23 3.1. DEVELOPMENT OF NEW ASSAY SYSTEMS 23 3.1.1. BAR ASSAY 23 3.1.2. CLONING OF THE HUMAN AR AND PRODUCTION OF FUNCTIONAL PROTEIN 24 3.1.3. DEVELOPMENT OF A SCREENING ASSAY ON MICROTITRE PLATES (IRA) 25 3.2.
    [Show full text]
  • Annex D to the Report of the Panel to Be Found in Document WT/DS320/R
    WORLD TRADE WT/DS320/R/Add.4 31 March 2008 ORGANIZATION (08-0902) Original: English UNITED STATES – CONTINUED SUSPENSION OF OBLIGATIONS IN THE EC – HORMONES DISPUTE Report of the Panel Addendum This addendum contains Annex D to the Report of the Panel to be found in document WT/DS320/R. The other annexes can be found in the following addenda: – Annex A: Add.1 – Annex B: Add.2 – Annex C: Add.3 – Annex E: Add.5 – Annex F: Add.6 – Annex G: Add.7 WT/DS320/R/Add.4 Page D-1 ANNEX D REPLIES OF THE SCIENTIFIC EXPERTS TO QUESTIONS POSED BY THE PANEL A. GENERAL DEFINITIONS 1. Please provide brief and basic definitions for the six hormones at issue (oestradiol-17β, progesterone, testosterone, trenbolone acetate, zeranol, and melengestrol acetate), indicating the source of the definition where applicable. Dr. Boisseau 1. Oestradiol-17β is the most active of the oestrogens hormone produced mainly by the developing follicle of the ovary in adult mammalian females but also by the adrenals and the testis. This 18-carbon steroid hormone is mainly administered as such or as benzoate ester alone (24 or 45 mg for cattle) or in combination (20 mg) with testosterone propionate (200 mg for heifers), progesterone (200 mg for heifers and steers) and trenbolone (200 mg and 40 mg oestradiol-17β for steers) by a subcutaneous implant to the base of the ear to improve body weight and feed conversion in cattle. The ear is discarded at slaughter. 2. Progesterone is a hormone produced primarily by the corpus luteum in the ovary of adult mammalian females.
    [Show full text]
  • (Cyp19a1b-GFP) Zebrafish Embryos
    Screening Estrogenic Activities of Chemicals or Mixtures In Vivo Using Transgenic (cyp19a1b-GFP) Zebrafish Embryos Franc¸ois Brion1, Yann Le Page2, Benjamin Piccini1, Olivier Cardoso1, Sok-Keng Tong3, Bon-chu Chung3, Olivier Kah2* 1 Unite´ d’Ecotoxicologie in vitro et in vivo, Direction des Risques Chroniques, Institut National de l’Environnement Industriel et des Risques (INERIS), Verneuil-en- Halatte, France, 2 Universite´ de Rennes 1, Institut de Recherche Sante´ Environnement & Travail (IRSET), INSERM U1085, BIOSIT, Campus de Beaulieu, Rennes France, 3 Taiwan Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan Abstract The tg(cyp19a1b-GFP) transgenic zebrafish expresses GFP (green fluorescent protein) under the control of the cyp19a1b gene, encoding brain aromatase. This gene has two major characteristics: (i) it is only expressed in radial glial progenitors in the brain of fish and (ii) it is exquisitely sensitive to estrogens. Based on these properties, we demonstrate that natural or synthetic hormones (alone or in binary mixture), including androgens or progestagens, and industrial chemicals induce a concentration-dependent GFP expression in radial glial progenitors. As GFP expression can be quantified by in vivo imaging, this model presents a very powerful tool to screen and characterize compounds potentially acting as estrogen mimics either directly or after metabolization by the zebrafish embryo. This study also shows that radial glial cells that act as stem cells are direct targets for a large panel of endocrine disruptors, calling for more attention regarding the impact of environmental estrogens and/or certain pharmaceuticals on brain development. Altogether these data identify this in vivo bioassay as an interesting alternative to detect estrogen mimics in hazard and risk assessment perspective.
    [Show full text]
  • Endocrine Disrupting Compounds and Prostate Cell Proliferation
    Review Article Clinics in Oncology Published: 18 Oct, 2016 Endocrine Disrupting Compounds and Prostate Cell Proliferation Joubert Banjop Kharlyngdoh and Per-Erik Olsson* Department of Biology, Örebro University, Sweden Abstract Epidemiological, in vitro and animal studies have indicated that Endocrine Disrupting Compounds (EDCs) influence the normal growth and development of the prostate as well as development and progression of prostate cancer. This has been linked to an increased presence of environmental chemicals that interfere with hormonal signaling. Many of these effects appear to be associated with interferences with steroid hormone receptor signaling or by affecting steroidogenesis. Currently, there is abundant evidence from epidemiological studies linking pesticides and EDCs with elevated prostate cancer risk. Bisphenol-A, a known EDC, has been shown to promote induction of Prostate Specific Antigen (PSA), which is a biomarker for prostate cancer, in the LNCaP human prostate carcinoma cells, and to increase prostate carcinogenesis in animal models. Our research has focused on AR signaling and identification of novel androgenic and anti-androgenic EDCs. Using prostate cancer cell lines we have shown that the AR agonist, TBECH, and antagonist ATE, which is also a partial ART877A agonist, induce PSA expression. With the increasing presence of these EDCs in indoor and outdoor air, follows an increased risk of disturbed prostate development, regulation and function. Hence, identification of the contribution of EDCs to prostate cancer
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol Acetate Is Also Used in the Treatment of Ano- 16
    Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol acetate is also used in the treatment of ano- 16. Mwamburi DM, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar As for progestogens in general (see Progesterone, rexia and cachexia (see below) in patients with cancer results in 2 months. Clin Infect Dis 2004; 38: 895–902. p.2125). The weight gain that may occur with meges- or AIDS. The usual dose is 400 to 800 mg daily, as tab- 17. Grunfeld C, et al. Oxandrolone in the treatment of HIV-associ- ated weight loss in men: a randomized, double-blind, placebo- trol acetate appears to be associated with an increased lets or oral suspension. A suspension of megestrol ace- controlled study. J Acquir Immune Defic Syndr 2006; 41: appetite and food intake rather than with fluid reten- tate that has an increased bioavailability is also availa- 304–14. tion. Megestrol acetate may have glucocorticoid ef- ble (Megace ES; Par Pharmaceutical, USA) and is Hot flushes. Megestrol has been used to treat hot flushes in fects when given long term. given in a dose of 625 mg in 5 mL daily for anorexia, women with breast cancer (to avoid the potentially tumour-stim- cachexia, or unexplained significant weight loss in pa- ulating effects of an oestrogen—see Malignant Neoplasms, un- Effects on carbohydrate metabolism. Megestrol therapy der Precautions of HRT, p.2075), as well as in men with hot 1-3 4 tients with AIDS. has been associated with hyperglycaemia or diabetes mellitus flushes after orchidectomy or anti-androgen therapy for prostate in AIDS patients being treated for cachexia.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]